IP Library Granted Patent US 9,597,313
Granted Patent B2
US 9,597,313 · App. 11/821,982 · Granted Mar 21, 2017

Composition and methods for the enterosorption and management of toxins

Inventors: Timothy D. Phillips (College Station, TX); Robert Hunt Carpenter (Bastrop, TX)
A61K31/366A61K33/06A61K35/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,597,313
App. No.
11/821,982
Granted
Mar 21, 2017
Kind
B2
Abstract

A composition and method for use as a preventive therapy to mitigate the effects of environmental toxins, and particularly aflatoxins in a subject. The subject may be at risk for hepatocellular carcinoma and aflatoxicosis. The composition comprising: an effective amount of an isolated low sodium, calcium aluminosilicate clay in a powder form, wherein the isolated low sodium, calcium aluminosilicate clay contains acceptable levels of dioxins and priority toxic heavy metal contamination, and is capable of preferentially binding aflatoxins in the gastrointestinal tract.

Claims (46)

1. An oral composition capable of binding an aflatoxin comprising:

an effective amount of an isolated calcium aluminosilicate clay having an particle size less than 80 microns has a detectable level of OCDD and is free from detectable levels of total tetra-dioxin, total penta-dioxin, and total hexa-dioxin;

wherein the detectable levels of total tetra-dioxin are above 0.024 pg/L;

the detectable levels of total penta-dioxin are above 0.025 pg/L; and the detectable levels of total hexa-dioxin are above 0.039 pg/L;

wherein the detectable level of OCDD is about 0.362 pg/L;

wherein an orally consumed effective amount of the isolated calcium aluminosilicate clay composition is useful for mitigating toxic effects of the aflatoxin in a living system at risk for aflatoxicosis.

2. The composition of claim 1 , wherein the isolated calcium aluminosilicate clay has a chemical composition comprising:

CaO above about 3.2%; MgO ranging from about 4.0 to about 5.4%; Fe 2 0 3 ranging from about 5.4 to about 6.5; K 2 0 ranging from about 0.50 to about 0.90%; Na 2 O ranging from about 0.10 to about 0.30%; MnO ranging from about 0.01 to about 0.03%; Al 2 0 3 ranging from about 14.8 to about 18.2%;

and SiO 2 ranging from about 62.4 to about 73.5%; wherein, the chemical composition is given as weight percent.

3. The composition of claim 1 , wherein the aflatoxins are selectively sorbed to the calcium aluminosilicate clay composition.

4. The composition of claim 1 , wherein the isolated calcium aluminosilicate clay composition exhibits a pH ranging from about 5 to about 9 in solution.

5. An oral composition for use as a preventive therapy to mitigate effects of environmental toxins in a living system, comprising:

an effective amount of an isolated calcium aluminosilicate clay having an average particle size less than 80 microns has a detectable level of OCDD and is free from detectable levels of total tetra-dioxin, total penta-dioxin, and total hexa-dioxin;

the isolated calcium aluminosilicate clay is capable of binding the environmental toxins;

wherein total tetra-dioxin have detectable levels above 0.024 pg/L; total penta-dioxin have detectable levels above 0.025 pg/L; and total hexa-dioxin have detectable levels above 0.039 pg/L;

wherein the detectable level of OCDD is about 0.362 pg/L;

wherein an orally consumed effective amount of the isolated calcium aluminosilicate clay composition is useful for mitigating effects of the environmental toxins in a living system at risk for environmental toxin exposure.

6. The composition of claim 5 , wherein the isolated calcium aluminosilicate clay has a chemical composition comprising:

CaO above about 3.2%; MgO ranging from about 4.0 to about 5.4%; Fe 2 0 3 ranging from about 5.4 to about 6.5; K 2 0 ranging from about 0.50 to about 0.90%; Na 2 O ranging from about 0.10 to about 0.30%; MnO ranging from about 0.01 to about 0.03%; Al 2 0 3 ranging from about 14.8 to about 18.2%;

and SiO 2 ranging from about 62.4 to about 73.5%; wherein, the chemical composition is given as weight percent.

7. The composition of claim 5 , wherein the aflatoxins are selectively sorbed to the calcium aluminosilicate clay composition.

8. The composition of claim 5 , wherein the isolated calcium aluminosilicate clay composition exhibits a pH ranging from about 5 to about 9 in solution.

9. A method of mitigating an effect of an environmental toxin in a system, comprising steps:

(a) administering orally an effective amount of an isolated calcium aluminosilicate clay having an average particle size less than 80 microns has a detectable level of OCDD about 0.362 pg/L and is free from detectable levels of total tetra-dioxin having a detectable levels above 0.024 pg/L; total penta-dioxin having detectable levels above 0.025 pg/L; and total hexa-dioxin having detectable levels above 0.039 pg/L;

(b) waiting a period of time; and

(c) repeating step (a)-(b) until the effects of the environmental toxin are mitigated.

10. The method of claim 9 , further comprising the step of: selecting the isolated calcium aluminosilicate clay to have a chemical composition comprising: CaO above 3.2%; MgO ranging from about 4.0 to about 5.4%; Fe 2 0 3 ranging from about 5.4 to about 6.5; K 2 0 ranging from about 0.50 to about 0.90%; Na 2 O ranging from about 0.10 to about 0.30%; MnO ranging from about 0.01 to about 0.03%; Al 2 0 3 ranging from about 14.8 to about 18.2%; and SiO 2 ranging from about 62.4 to about 73.5%; wherein, the chemical composition is given as weight percent.

11. The method of claim 9 , further comprising a step of: selecting the system to be one predisposed to cancer.

12. The method of claim 9 , further comprising a step of: selecting the period of time to be less than about 24 hours.

13. The method of claim 9 , further comprising a step of: selecting the isolated calcium aluminosilicate clay to have a pH ranging from about 5 to about 9.

14. A method of mitigating an exposure risk in a system for liver cancer and aflatoxicosis when the system is exposed to an environmental aflatoxin, the method comprising the steps:

(a) administering orally an effective amount of an isolated calcium clay having an average particle size less than 80 microns has a detectable level of OCDD about 0.362 pg/L and is free from detectable levels of total tetra-dioxin having detectable levels above 0.024 pg/L; total penta-dioxin having detectable levels above 0.025 pg/L; and total hexa-dioxin having detectable levels above 0.039 pg/L;

(b) waiting a period of time; and

(c) repeating step (a)-(b) until the system is free of exposure risk to aflatoxins.

15. The method of claim 14 , further comprising selecting the isolated calcium aluminosilicate clay to have a chemical composition comprising: CaO above 3.2%; MgO ranging from about 4.0 to about 5.4%; Fe 2 0 3 ranging from about 5.4 to about 6.5; K 2 0 ranging from about 0.50 to about 0.90%; Na 2 O ranging from about 0.10 to about 0.30%; MnO ranging from about 0.01 to about 0.03%; Al 2 0 3 ranging from about 14.8 to about 18.2%; and SiO 2 ranging from about 62.4 to about 73.5%; wherein, the chemical composition is given as weight percent.

16. The method of claim 14 , further comprising selecting the system to be one predisposed to liver cancer and aflatoxicosis.

17. The method of claim 14 , further comprising selecting the period of time to be less than about 24 hours.

18. The method of claim 14 , further comprising a step of: selecting the isolated calcium aluminosilicate clay to have a pH ranging from about 5 to about 9.

19. A method of treating a subject exposed to high levels of aflatoxin, or low levels of aflatoxin over an extended period of time, comprising:

(a) administering orally an effective amount of an isolated calcium aluminosilicate clay having an average particle size less than 80 microns has a detectable level of OCDD about 0.362 pg/L and is free from detectable levels of total tetra-dioxin having a detectable levels above 0.024 pg/L; total penta-dioxin having detectable levels above 0.025 pg/L; and total hexa-dioxin having detectable levels above 0.039 pg/L;

(b) waiting a period of time; and

(c) repeating step (a)-(b) until the subject's effects of exposure to aflatoxins are lessened or eliminated.

20. The method of claim 19 , further comprising selecting the isolated calcium aluminosilicate clay to have a chemical composition comprising: CaO above 3.2%; MgO ranging from about 4.0 to about 5.4%; Fe 2 0 3 ranging from about 5.4 to about 6.5; K 2 0 ranging from about 0.50 to about 0.90%; Na 2 O ranging from about 0.10 to about 0.30%; MnO ranging from about 0.01 to about 0.03%; Al 2 0 3 ranging from about 14.8 to about 18.2%; and SiO 2 ranging from about 62.4 to about 73.5%; wherein, the chemical composition is given as weight percent.

21. The method of claim 19 , further comprising selecting the system to be one predisposed to liver cancer and aflatoxicosis.

22. The method of claim 19 , further comprising selecting the period of time to be less than about 24 hours.

23. The method of claim 19 , further comprising a step of: selecting the isolated calcium aluminosilicate clay to have a pH ranging from about 5 to about 9.

Assignments (4)
CONFIRMATORY LICENSE Recorded Jan 23, 2018
From: TEXAS A&M UNIVERSITY SYSTEM
To: NIH - DEITR
Reel/Frame 044703/0711 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 6, 2009
From: TEXAS ENTEROSORBENTS INC.
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 022646/0410 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2007
From: PHILLIPS, TIMOTHY D.
To: THE TEXAS A&M UNIVERSITY SYSTEM
Reel/Frame 019696/0162 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 15, 2007
From: CARPENTER, ROBERT HUNT
To: TEXAS ENTEROSORBENTS INC.
Reel/Frame 019696/0283 →
Continuity (2)
Provisional Application 60816824 · Jun 27, 2006
Related Publication 20080008763A1 · Jan 10, 2008